Based on these results, we concluded that Melsmon treatment delays cellular senescence by alleviating oxidative stress through the upregulation of the NRF2-mediated antioxidant pathway, suggesting an improvement in the damage associated with skin aging. This evidence concerns the gene NFE2L2 and skin aging.